Roles
- Professor of Clinical Medicine
- Chief, Division of Medical Oncology
- Associate Director for the Cancer Center and Medical Director for International Affairs, Sylvester Comprehensive Cancer Center
-
Biography
Dr. Gilberto Lopes is a medical oncologist and researcher who focuses on new anticancer drug development and global oncology. He has published more than 270 scientific papers and has led hundreds of clinical trials. Dr. Lopes was the main investigator of Keynote 42, a clinical trial that demonstrated the efficacy of the immunotherapy drug pembrolizumab in people living with lung cancer. This groundbreaking study led to one of the FDA approvals of pembrolizumab. Additionally, Dr. Lopes has contributed significantly to the development of several chemotherapies and targeted medications that address specific molecular changes in tumors. He also does research in cancer control, policy and health economics and is active in improving access to cancer medications in underserved settings. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Teaching Interests
Oncology, health policy, health economics, drug development. -
Research Interests
Lung cancer, drug development, access to cancer medications, health economics, health policy. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Articles & News
U.S. Cancer Deaths Linked to Alcohol Have Doubled Since 1990, Study Finds
Lung Cancer May Develop Differently in Younger Adults
A Long Shadow: Mapping Mesothelioma’s Uneven Decline Across the United States
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 25 clinical trials.
-
To investigate the safety and tolerability of EP0031 given as monotherapy.
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase I/II
- Enrollment Status: Open
-
This is a FIH, Phase 1/2, multicenter, open-label, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-520, determine the RP2D, and evaluate the antitumor activity in patients with advanced ROS1-positive NSCLC and other advanced ROS1-positive solid tumors. The study will be conducted in 2 phases.
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase I/II
- Enrollment Status: Not Accepting
-
Evaluate whether NVL-655 is effective at shrinking your tumors, and if so, how long the response to NVL-655 lasts. Further understand the side effects associated with NVL-655. Confirm how much of NVL-655 gets into your bloodstream and how long it takes for the body to get rid of it.
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase I/II
- Enrollment Status: Not Accepting
-
The purpose of this study is to learn about the safety (the impact of the study drug on your body) and the effects of study drug PF-07799933 with or without combination study drugs (binimetinib or cetuximab) for your specific cancer on your body and to find the best dose for treating certain cancer. For BRAF altered melanoma (a disease in which malignant (cancer) cells form in melanocytes (cells that color the skin)) or other solid tumors, PF-07799933 may be combined with binimetinib, also known as MEKTOVI (an United States (US) Food and Drug Administration [FDA] approved cancer medication but not approved in combination with PF-07799933). For BRAF altered colorectal cancer (CRC) (cancer of the colon or rectum), PF-07799933 may be combined with cetuximab, also known as ERBITUX (an FDA approved cancer medication but not approved in combination with PF-07799933).
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase I
- Enrollment Status: Not Accepting
-
A study to test whether different doses of BI 764532 help peoplewith small cell lung cancer or other neuroendocrine cancers
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase II
- Enrollment Status: Not Accepting
-
The purpose of this study is to test the study drug, PC14586 alone and in combination with pembrolizumab. PC14586 will be tested at different doses with and without pembrolizumab to find out if it is safe, to understand the way your body processes the drug, and to see how the study drug affects your body (how well it works). This is the first evaluation of PC14586 with and without pembrolizumab in people.
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase II
- Enrollment Status: Open
-
This research study is studying an investigational drug called BL-M07D1 as a possible treatment for cancer. The purpose of this study is to determine the dose of the study drug that can be tolerated and is least harmful. The study drug is an antibody drug conjugate (ADC) that is intended to attack cancer cells and possibly stimulate your immune system.
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase I
- Enrollment Status: Not Accepting
-
This study is being conducted to test the good and bad effects of the investigational drug NVL-330 at different doses, and to decide on a dose to be tested in future studies. The study will examine: • What side effects are associated with NVL-330 • Whether NVL-330 is effective at shrinking cancer, and if so, how long the response to NVL-330 lasts• How much of NVL-330 gets into your blood and how long it stays there
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase I
- Enrollment Status: Open
-
This study is designed to evaluate different doses of the study drug BMS-986507 given in combination with current standard of care treatments for advanced lung cancer. In Group A, we will learn if the combination of the study drug BMS-986507 with osimertinib is safe and tolerable. In Group B, we will learn if the combination of the study drug BMS-986507 with pembrolizumab is safe and tolerable.
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase I/II
- Enrollment Status: Open
-
The purpose of this study is to see whether the investigational treatment, NVL-655, is better than the usual treatment, alectinib, in treating patients with ALK-positive NSCLC. To decide if it is better, the study doctors will be looking mainly at how long patients go without worsening of their cancer, when receiving NVL-655 as compared to alectinib. The study doctors will also look at additional information, such as whether the study treatments are able to shrink tumors, as well as the side effects seen with NVL-655 or alectinib.
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase III
- Enrollment Status: Open
-
This research study is being done to test the safety of an investigational treatment called LY4050784. This research study is being done in two phases: dose escalation and dose expansion. The dose escalation phase will test the safety and tolerability of an investigational treatment called LY4050784. This phase may also help determine what the recommended dose is for the next phase of the study.
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase I
- Enrollment Status: Not Accepting
-
The purpose of this study is to determine the dose of the study drug that can be tolerated and is least harmful. The study drug is an antibody drug conjugate (ADC) that is intended to attack cancer cells and possibly stimulate your immune system.
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase I
- Enrollment Status: Open
-
This study aims to determine the safe dose range of BGB-26808 that can be used in combination with a single standard dose of tislelizumab, what the side effects are when taking these drugs together, how your body copes with these drugs and if these drugs shrink your tumors.
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase I
- Enrollment Status: Not Accepting
-
To look at the good and/or bad effects that the treatment of 225Ac-ABD147 has on you and on your diseaseTo find out the highest dose of 225Ac-ABD147 that can be safely given to patientsTo measure the amount of radiation that your organs and tumors are exposed toTo measure the amount of 225Ac-ABD147 in your blood and urine at different times
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase I
- Enrollment Status: Closed
-
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase 2
- Enrollment Status: Closed
-
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients With Advanced Solid Malignancies and Expansion in Select Malignancies
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase 1
- Enrollment Status: Closed
-
Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase 1
- Enrollment Status: Closed
-
Phase 1/2 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
Long-Term Follow-Up (LTFU) of Participants Treated With GSK Adoptive Cell Therapies
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase 1
- Enrollment Status: Closed
-
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase 1
- Enrollment Status: Closed
-
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
-
A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC
- Principal Investigator: Gilberto Lopes
- Study Phase: Phase 3
- Enrollment Status: Closed
-
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
- Principal Investigator: Gilberto Lopes
- Study Phase: N/A
- Enrollment Status: Not Accepting